文献速递乳腺癌

70基因签名与临床评估指导乳腺癌化疗的成本效果分析

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial.
PubMed 文献 · Eur J Cancer · 2020-08-11

基于MINDACT随机对照试验患者水平数据,采用混合决策树-Markov模型模拟10年时限内70基因签名对比临床评估指导临床高危ER+/HER2-乳腺癌辅助化疗选择的成本效果。70基因签名策略在六国中产生更多QALY,五国成本更低(占优),英国ICER为22,910英镑/QALY,结论为具有成本效果。

要点

  • 临床高危ER+/HER2-乳腺癌中,70基因签名指导化疗可安全降级且具成本效果。
  • 五国中70基因签名策略成本更低且QALY更高,英国ICER为22,910英镑/QALY。

核心结论

  • 在临床高危ER+/HER2-乳腺癌患者中,使用70基因签名安全指导化疗降级对比单用临床评估具有成本效果。

研究设计与样本

  • 基于MINDACT随机对照试验患者水平数据的成本效果分析,采用混合决策树-Markov模型模拟10年时限。
  • 比较70基因签名联合临床评估与单用临床评估两种治疗策略。
  • 纳入比利时、法国、德国、荷兰、英国和美国六个国家,主要结局为QALY、各国成本及增量成本效果比(ICER)。

主要发现

  • 70基因签名指导的治疗策略相比单用临床评估产生更多QALY。
  • 六国中有五国70基因签名策略成本更低。
  • 70基因签名在比利时、法国、德国、荷兰和美国占优,在英国具成本效果(ICER 22,910英镑/QALY)。

临床怎么用

  • 对临床高危ER+/HER2-乳腺癌患者,可借助70基因签名识别可安全免除辅助化疗者,在五国中同时节省成本。

局限性

  • 模型输入存在不确定性,需MINDACT试验长期随访和结局数据加以解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical utility of the 70-gene signature (MammaPrint®) to guide chemotherapy use in T1-3N0-1M0 breast cancer was demonstrated in the Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) study. One thousand four ninety seven of 3356 (46.2%) enrolled patients with high clinical risk (in accordance with the modified Adjuvant! Online clinical-pathological assessment) had a low-risk 70-gene signature. Using patient-level data from the MINDACT trial, the cost-effectiveness of using the 70-gene signature to guide adjuvant chemotherapy selection for clinical high risk, estrogen receptor positive (ER+), human epidermal growth factor 2 negative (HER2-) patients was analysed. PATIENTS AND METHODS: A hybrid decision tree-Markov model simulated treatment strategies in accordance with the 70-gene signature with clinical assessment versus clinical assessment alone, over a 10-year time horizon. Primary outcomes were quality-adjusted life years (QALYs), country-specific costs and incremental cost-effectiveness ratios (ICERs) for six countries: Belgium, France, Germany, Netherlands, UK and the US. RESULTS: Treatment strategies guided by the 70-gene signature result in more QALYs compared with clinical assessment alone. Costs of the 70-gene signature strategy were lower in five of six countries. This led to dominance of the 70-gene signature in Belgium, France, Germany, Netherlands and the US and to a cost-effective situation in the UK (ICER £22,910/QALY). Annual national cost savings were €4.2M (Belgium), €24.7M (France), €45.1M (Germany), €12.7M (Netherlands) and $244M (US). UK budget increase was £8.4M. CONCLUSION: Using the 70-gene signature to safely guide chemotherapy de-escalation in clinical high risk patients with ER+/HER2- tumours is cost-effective compared with using clinical assessment alone. Long-term follow-up and outcomes from the MINDACT trial are necessary to address uncertainties in model inputs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Retèl VP, Byng D, Linn SC, et al. Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial. Eur J Cancer. 2020. PMID: 32795875. doi:10.1016/j.ejca.2020.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。